Table 1.

clinical characteristics and disability status of long term PML survivors

Patient	Age at onset	Treatment	Duration of disease (months)	Disability at time of PML diagnosis	Outcome (Modified Rankin Scale)
1	43	HAART	90	Bilateral pyramidal syndrome and impulsiveness	Stable (1)
2	38	HAART	113	Decreased visual acuity and executive functions	Partial improvement (1)
3	33	HAART + 5HT2A antagonist	75	Expressive aphasia and right upper extremity apraxia	Partial improvement (2)
4	45	HAART after four months of PML onset	78	Expressive aphasia, cognitive dysfunction, right pyramidal syndrome and sensory loss	Partial improvement (2)
5	44	HAART	84	Cognitive dysfunction, cerebellar syndrome	Marked improvement but developed seizures (1)
6*	54	ARA-C	188	Bilateral cerebellar syndrome	Partial improvement (3)
7	36	HAART + ARA-C + peptide T	149	Bilateral cerebellar syndrome	Stable (3)
8	35	HAART	162	Dysarthria and truncal ataxia	Partial improvement (2)
9	49	HAART	80	Bilateral cerebellar syndrome	Stable but developed seizures (4)
10	33	HAART	180	Bilateral cortical blindness	Stable but developed seizures (4)
11	40	HAART + 5HT2A antagonist	75	Abulia, transcortical aphasia, right homonymous hemianopsia and right pyramidal syndrome	Partial improvement but developed seizures (4)
12	33	HAART	83	Right pyramidal syndrome	Stable (2)
13	39	HAART + IFNα	79	Left pyramidal and cerebellar syndrome	Partial improvement (4)
14	34	HAART	74	Left pyramidal syndrome	Partial improvement (2)
15	37	HAART	150	Expressive aphasia	Marked improvement (1)
16	31	HAART	68	Seizures, left pyramidal syndrome, cognitive dysfunction	Marked improvement of cognitive and motor dysfunction, but developed seizures (1)
17	33	HAART	99	Cognitive dysfunction and a right sided sensory loss	Stable (1)
18	31	HAART+ IFNα	96	Expressive aphasia and cognitive dysfunction	Marked improvement of aphasia (1)
19	39	HAART+ IFNα	114	Cognitive dysfunction	Stable (3)
20	39	HAART	92	Right pyramidal syndrome and sensory loss	Stable (1)
21	41	HAART	105	Right cerebellar syndrome and dysarthria	Partial improvement (3)
22	36	HAART	162	Expressive aphasia and right pyramidal syndrome	Partial improvement of the aphasia (3)
23	31	HAART	162	Left cerebellar syndrome and dysarthria	Partial improvement of the cerebellar syndrome (2)
24	33	HAART + IFNα	186	Expressive aphasia and right pyramidal syndrome	Stable (4)

HAART: highly active antiretroviral therapy, INFα: interferon α 5HT2A: serotonin receptor 2A, ARA-C: cytarabine,

^*HIV negative